


COMPLETION CBCT IS MANDATORY TO ASSESS TECHNICAL SUCCESS DURING F-BEVAR

Gustavo S. Oderich MD

Director of Aortic Center

Professor of Surgery

Rochester, Minnesota – United States



CACVS2018
P A R I S



CHAIRMAN
Jean-Pierre Becquemin

CO-CHAIRMAN
VENOUS SESSION
Jean-Luc Gérard

CO-CHAIRMAN
CONTROVERSIES
IN A/V ACCESS
Pierre Bourquelot
Richard Shoemaker

SCIENTIFIC COMMITTEE
Eric Allaire
Jean-Marc Alzieu
Michel Baroli
Pierre Bourquelot
Ludovic Cernat
Xavier Chazotte
Nicholas Cheshire
Frederick Cochennec
Eric Desmet
Marie-Henri Eckstein
Michel Fedani
Yann Goufflet
Tilo Kolb
Christos Liapis
Jan Lohr
Mario Malina
Amrout Mansoura
Maureen Sidi
Henric Sjöberg
Frank Vermeulen
Fabio Verzini

VENOUS SCIENTIFIC COMMITTEE
Gladys Jaramal-Dezob
Lowell Kabric
Michel Perrin
Thomas Ponsolle

ACCREDITATION EACACHE
More sessions, 13 medical sessions, 7 credits

**PROGRAMME FINAL
FINAL PROGRAM**

CONTROVERSES ET ACTUALITÉS EN CHIRURGIE VASCULAIRE
**CONTROVERSIES & UPDATES
IN VASCULAR SURGERY**

JANUARY 25-27 2018
MARRIOTT RIVE GAUCHE & CONFERENCE CENTER
PARIS, FRANCE
WWW.CACYS.ORG

ACCREDITATION EACACHE
More sessions, 13 medical sessions, 7 credits

CONTROVERSES ET ACTUALITÉS EN CHIRURGIE VASCULAIRE
**CONTROVERSIES & UPDATES
IN VASCULAR SURGERY**

2014
CONFERENCE CENTER
WWW.CACYS.ORG

ACCREDITATION EACACHE
More sessions, 13 medical sessions, 7 credits

CONTROVERSES ET ACTUALITÉS EN CHIRURGIE VASCULAIRE
**CONTROVERSIES & UPDATES
IN VASCULAR SURGERY**

2013
CONFERENCE CENTER
WWW.CACYS.ORG

ACCREDITATION EACACHE
More sessions, 13 medical sessions, 7 credits

FACULTY DISCLOSURE

Gustavo S. Oderich MD


- Consulting, DSMB, CEC*
Cook Medical Inc. and WL Gore
- Research and educational grants*
Cook Medical Inc., WL Gore, GE Healthcare

* All consulting fees and grants were paid to Mayo Clinic


VISCERAL BRANCH DEVICES

PATIENT-SPECIFIC

OFF-THE-SHELF



Cook Zenith®



Fenestrated
Anaconda™



JOTEC™




Cook
p-Branch®



Cook
t-Branch®



Gore
TAMBE®



Medtronic
TAAA



FDA
APPROVED

CE MARK

CE MARK

CE MARK

PIVOTAL TRIAL

TRIAL
DESIGN

TRIAL
DESIGN

MULTICENTER
IDE

Juxtarenal

Pararenal
TAAA

Pararenal

TAAA

Pararenal

TAAA

TAAA


TAAA

31st Annual Meeting
19-22 September, 2017

Lyon Congress Center
Lyon, France



LEARNING CURVE IN 334 PATIENTS TREATED BY FENESTRATED- BRANCHED ENDOVASCULAR REPAIR FOR COMPLEX AORTIC ANEURYSMS



	All n = 334	Q1 n = 81	Q2 n = 84	Q3 n = 85	Q4 n = 84	P value
30 day mortality	2%	6%	2%	1%	0%	0.009
Any major adverse event	33%	58%	32%	21%	21%	<.001
30-day reinterventions	9%	9%	10%	6%	2%	<.001

ESVS2017
LYON, FRANCE

Oderich et al (unpublished data)

 MAYO CLINIC

SOCIETY for
VASCULAR SURGERY

2016



VASCULAR
ANNUAL MEETING

CLINICAL RESEARCH STUDIES


From the Society for Vascular Surgery

Prospective, nonrandomized study to evaluate endovascular repair of pararenal and thoracoabdominal aortic aneurysms using fenestrated-branched endografts based on supraceliac sealing zones

Gustavo S. Oderich, MD,^a Mauricio Ribeiro MD, PhD,^{a,b} Jan Hofer, RN,^a Jean Wigham, RN,^a Stephen Cha, MS,^c Julia Chini,^a Thanila A. Macedo, MD,^d and Peter Gloviczki, MD,^a Rochester, Minn; and Ribeirão Preto, Brazil



CrossMark



VAM2016
WASHINGTON, DC


30 day mortality 0.5% (1/225)


The more complex, the greater the risk of failure...

- Endoleaks
- Branch related complications



RENAL STENT OCCLUSION






ADVANCED IMAGING APPLICATIONS

IMPACT OF FUSION OVERLAY AND CONE BEAM CT ON RADIATION EXPOSURE AND TECHNICAL EVALUATION OF F-BEVAR

Emanuel Tenorio MD PhD, Gustavo S. Oderich MD, Giuliano Sandri MD, Pinar Ozbek, Jussi Karkkainen MD PhD, Thanila A Macedo MD, Terri Vrtiska MD

Division of Vascular and Endovascular Surgery and Department of Radiology and Epidemiology, Mayo Clinic




PATIENTS

386 patients enrolled (April 2007-April 2017)


219 without FUSION/
CBCT (56%)

167 with FUSION/
CBCT (44%)



281 pararenal
or Extent IV
(73%)

105 Extent I-III
TAAA (27%)




HYBRID ROOM SYSTEMS


	Specification	Years	Units	Advanced applications
System 1	Siemens Axiom	2002-2011	1	No
System 2	Siemens Zeego	2011-2015	1	Fusion/ CBCT
System 3	GE Discovery IGS 740	2016-2018	2	Fusion/ HD CBCT/ Digital Zoom

USE OF FUSION & CBCT


423 patients




FLUOROSCOPY TIME




CONTRAST VOLUME




EFFECTIVE DOSE




OPERATOR DOSE PER CASE




INCREASING VOLUME





TYPE IA ENDOLEAK (<2%)



STENT COMPRESSION (~5%)



TYPE III ENDOLEAK (~ 10%)





F-BEVAR WITHOUT CBCT



18 of 219 patients (8%)



Positive finding by CTA warranting reintervention	n	Secondary Interventions
Branch stent compression or kink	5	
Renal-mesenteric	5	Redo stent/PTA
Iliac	1	Redo stent/PTA
Endoleak	7	
Type IIIC	6	Redo stent in 5, renal bypass in 1
Type IA (with stent infolding in 1)	2	Cuff in 1, Palmaz stent in 1
Flow-limiting dissection	2	
Common iliac artery with occlusion	1	Embolectomy + Redo stent
External iliac artery	1	Stenting
SMA coverage by single-wide scallop	2	Stenting x 1, Bypass x 1
Celiac stent malpositioning	1	Stent relocation, redo stent
Total	18	

ALL PATIENTS REQUIRED SECONDARY PROCEDURES














No postoperative
complications



F-BEVAR WITH CBCT

14 of 167 patients (8%)

Positive finding by CBCT warranting intraoperative revision	n	Type of revision
Branch stent compression or kink	4	
Renal-mesenteric	4	Redo stent/PTA
Endoleak	6	
Type IA	1	Cuff thoracic extension
Type IIIC	5	Thoracic extension x 1, redo stent x4
Flow-limiting dissection	2	
External iliac artery	1	Redo stent
SMA dissection/ occlusion	1	Removal of dissected flap + ROMS
IIA coverage	1	Recanalization and stent
Celiac stent malpositioning	1	Relocation, Redo Stent
Total	14	

ALL REVISIONS PERFORMED AT TIME OF INDEX PROCEDURE

30-DAY OUTCOMES

	Without CBCT n = 219	With CBCT n = 167	P value
30-day mortality	4%	1%	.049
30-day reintervention	10%	4%	<.022
Reintervention prior to discharge	9%	2%	<.004
Major adverse events	43%	19%	.001
Estimated blood loss > 1L	27%	9%	.001
Acute kidney injury	16%	5%	.002
New onset dialysis	1%	1%	.7
Myocardial infarction	5%	5%	.7
Respiratory failure	6%	2%	0.029
Paraplegia	2%	2%	.28
Stroke	2%	4%	.28
Bowel ischemia	3%	1%	.29



PROSPECTIVE, NON-RANDOMIZED STUDY TO EVALUATE CONE BEAM COMPUTED TOMOGRAPHY FOR ASSESSMENT OF STANDARD AND COMPLEX EVAR

Emanuel Tenorio MD PhD, Gustavo S. Oderich MD,
Giuliano Sandri MD, Pinar Ozbek, Bernardo Mendes MD, Jussi
Karkkainen MD, Terri Vrtiska MD, Thanila Macedo MD, Stephen Cha
MS and Peter Gloviczki MD

VAM2018


B O S T O N M A

*Abstract submitted for
presentation*



PATIENTS

155 patients had 170 endovascular
aortic aneurysm procedures



POSITIVE FINDINGS BY CBCT


- 43 patients (29%) had 49 positive findings
 - F-BEVAR 35% vs other 16% ($p=0.01$)


	n	Immediate Finding
Stent compression or kink	26	17%
Type I or III endoleak	16	10%
Arterial dissection or thrombus	7	5%

- 28 patients (18%) required immediate revision
- 15 patients (11%) had minor findings observed

DSA VS CBCT

- DSA alone would not have detected findings in 34 of the 43 patients (79%)
- 21 patients (62%) with negative DSA had immediate revisions based on CBCT findings
- 4 patients (2.5%) had CTA findings prompting interventions in three (2%), despite negative DSA and CBCT
 - Type IB endoleak > distal iliac limb extension
 - Femoral artery occlusion > patch angioplasty
 - Compressed renal stent > redo stenting
 - Internal iliac branch Type IC endoleak > observation





CONCLUSION

- Secondary reinterventions remain one of the most significant limitations of EVAR – standard or complex
- CBCT has allowed immediate assessment to identify technical problems that are not easily detected by DSA
- Immediate revision of these problems avoid unnecessary secondary interventions and may decrease morbidity associated with serious complications
- CBCT can also be applied by multiple specialties in a variety of other percutaneously guided interventions, including endoleak embolization, vessel catheterization, tissue biopsy or ablation, etc